Table of Contents

Chapter 1 Regulatory Basics of Process and Design Validation 1
Robert Falcone, Ph.D., FRAPS, FTOPRA

Chapter 2 Risk-Based Verification and Validation 7
John E. Lincoln

Chapter 3 Gap Assessments for Medical Devices 21
Brett Hofman, BS, MBA, Courtney Divine, BS, CPP, CSSGB, Heather Valley, MS, RAC-Global, and Timothy Wech, MSE, PE

Chapter 4 Test Method Validation and How it is Used for Medical Devices and Packaging 33
Brian K. Farison, Dylan Stover, and John E. Lincoln

Chapter 5 Design of Experiments 57
Anthony Carra

Chapter 6 Sterilization Validation Principles 77
Gerry O'Dell

Chapter 7 Six Sigma Concepts in Validation Studies for Medical Device Packaging 95
Brian K. Farison and Rod Patch

Chapter 8 Medical Packaging Validation 117
David DiVaccaro

Chapter 9 Cleaning Validations of Medical Products 125
Steven G. Richter, PhD

Chapter 10 Software Validation for Life Sciences 135
Wes Bloemker

Chapter 11 FDA Unique Device Identification Verification and Validation 161
Jonathan C. Bretz and Jay Crowley

Chapter 12 Equipment Validation 173
John E. Lincoln

Purchased from RAPS Library (library.raps.org) for the exclusive use of unknown.
© 2026 RAPS Library. Please report unauthorized use to raps@raps.org

Chapter 13 Sample Sizes for Verification and Validation 187
Steven Walfish

Chapter 14 Verification and Validation in Medical Device Computational Modeling and Simulation 201
Danny L. Levine, PhD, PE

Chapter 15 Additive (3D Printing) Manufacturing 213
John E. Lincoln

Chapter 16 Cybersecurity and Data Integrity 229
John E. Lincoln

Chapter 17 Validating the Medical Device Laser-Welding Process 243
David W. Steinmeier and Lisa Schaller

Chapter 18 Start-up of Cleanrooms, Initially and After a Worst-Case Event 253
Jim Polarine and Beth Kroeger-Fahnestock

Index 261

Figures

Figure 2-1. FDA Lifecycle 10
Figure 2-2. Internet FTA Sample Format 13
Figure 2-3. Possible Initial Descriptive Narrative 15
Figure 2-4. Possible Hazard List Format 16
Figure 2-5. Sample FTA 16
Figure 2-6. Sample Abbreviated Software FMECA 17
Figure 2-7. Fictitious Final Benefit-Risk Analysis/Statement 18
Figure 2-8. Incorporating Risk in the V&V Protocol 19
Figure 3-1. Roles vs. Impact Matrix 22
Figure 3-2. Gap Analysis/Remediation Process Phases 23
Figure 3-3. Risk Level vs. Gap Size 25
Figure 3-4. Cascading Effects of Standards Updates 28
Figure 3-5. Phase-gate Development Process 30
Figure 3-6. Waterfall Methodology 30
Figure 3-7. Critical Path Method 30
Figure 3-8. Hybrid Project Management Methodology Example 31
Figure 3-9. High-Level Gap Assessment Project Lifecycle 31
Figure 3-10. Simple Task Board View 31
Figure 3-11. Burndown Chart 31
Figure 3-12. Traditional vs. Iterative Planning in a Project Lifecycle 32
Figure 4-1. Definition of a Test method, ASTM E1488-12(2023) 34
Figure 4-2. Data Types vs. Resolution 35
Figure 4-3. Process View of Test methods, Peel Test Example 37
Figure 4-4. ISO 11607-1:2019, Section 4.4 Test Methods 41
Figure 4-5. TMV Waterfall Model (vs. FDA Design Control Guidance Waterfall) 44
Figure 4-6. Measurement Error, a Comparison of Two "Voices" 45
Figure 4-7. Measurement Error and Decision-Making 46

Purchased from RAPS Library (library.raps.org) for the exclusive use of unknown.
© 2026 RAPS Library. Please report unauthorized use to raps@raps.org

Figure 4-8. Precision and "Accuracy" 47
Figure 4-9. Bias and "Accuracy"–Focus on "Bias" 48
Figure 4-10. Precision and Bias 49
Figure 4-11. GRR Tree Diagram, Multi-Vari Chart plus Minitab Statistical Output 50
Figure 4-12. GRR Standard Deviations Explained as Trigonometric Function 52
Figure 5-1. DOE in Process Validation Flow 57
Figure 5-2. Progression of DOE Activities 58
Figure 5-3. Relation of Process Inputs and Outputs 59
Figure 5-4. Minitab ANOVA Analysis Output 61
Figure 5-5. Minitab Example of Design Options 62
Figure 5-6. Minitab Plackett-Burman Design Analysis 63
Figure 5-7. Two-Level Factorial Design Diagram 67
Figure 5-8. Three-Level Factorial Design Diagram 67
Figure 5-9. Minitab Regression Analysis Output 68
Figure 5-10. EVOP Diagram 68
Figure 5-11. Method of Steepest Ascent/Descent 68
Figure 5-12. Central Composite Design Diagram 69
Figure 5-13. Minitab CCD Analysis Output 69
Figure 5-14. Three-Factor Box-Behnken Design Diagram 70
Figure 5-15. Minitab Box-Behnken Analysis Output 71
Figure 5-16. Main Effects Plot 71
Figure 5-17. Interaction Effects Plot 71
Figure 5-18. Screening Minitab Output 72
Figure 5-19. Screening Response Optimizer 72
Figure 5-20. Optimization #1 Main and Interaction Plots 72
Figure 5-21. Optimization #1 Minitab Output 73
Figure 5-22. Optimization #1 Response Optimizer 73
Figure 5-23. Optimization #2 Main and Interaction Plots 73
Figure 5-24. Optimization #2 Contour Plot 74
Figure 5-25. Optimization #2 Response Optimizer 74
Figure 5-26. Capability Analysis Results 75
Figure 6-1. Sterilization Validation 78
Figure 7-1. Six Sigma Process 97
Figure 7-2. GRR Study Structure 101
Figure 7-3. GRR Study Showing Poor Repeatability and Reproducibility 102
Figure 7-4. GRR Study Showing Excellent Repeatability and Reproducibility 103
Figure 7-5. Baseline Process 104
Figure 7-6. Cause-and-Effect Diagram Showing the "6Ms" of Quality: Man, Machine, Measurement, Method, Material, and "Mother Nature" 104
Figure 7-7. Detailed Process Map Example: Sealing Portion of Process 105
Figure 7-8. Three Types of Cause-and-Effect Relationships 106
Figure 7-9. A Process Operating at Full Potential 106
Figure 7-10. Multi-Vari Chart Showing Three Families of Variation: Machine, Cycle, and Tool Cavity 108
Figure 7-11. Main Effects Plots Showing the Effects of Temperature, Time, and Pressure on the Response of Seal Strength (LBF/in) 109
Figure 7-12. DOE Interaction Plot Showing the Effects of Pressure on the Response, Seal Strength, at Two Temperature Settings (220˚F and 260˚F) 109
Figure 7-13. Stable Process—Not Capable and Capable 110

Purchased from RAPS Library (library.raps.org) for the exclusive use of unknown.
© 2026 RAPS Library. Please report unauthorized use to raps@raps.org

Figure 7-14. I-MR Chart of Seal Strength by Stage 112
Figure 7-15. Waterfall Model (Verification and Validation) 113
Figure 7-16. Traditional PQ Model 113
Figure 7-17. MPQ Approach Model 114
Figure 9-1. Examples of Typical Reusable Medical Devices 125
Figure 9-2. Notebook Studies Can Provide Data to Build Appropiate Validation Activities 129
Figure 9-3. Automated Cleaning Equipment Typically Should be Validated Prior to Use 132
Figure 11-1. Organizational Involvement in UDI Implementation 164
Figure 11-2. GHTF Process Validation Decision Tree 170
Figure 12-1. The Equipment Verification and Validation Cycle, Simplified 174
Figure 12-2. Application of Design Controls to Waterfall Design Process 176
Figure 12-3. Suggested/Possible V&V Test Case/Script Format 181
Figure 12-4. Typical Product Development Milestones With V&V Tasks 184
Figure 13-1. Application of Design Controls to Waterfall Design Process 188
Figure 13-2. Typical Operating Characteristic Curve (OC) 190
Figure 13-3. Equivalence 192
Figure 14-1. Example of a Discretized Solid Model 203
Figure 14-2. Fatigue Test of Femoral Knee Condyle 204
Figure 14-3. Load and Constraint Applied to a Finite Element Model of a Femoral Knee and Maximum Principal Stress in the Implant 204
Figure 14-4. Contour Plot of von Mises Equivalent Stress Distribution in a Carotid Artery Wall After Stent Expansion 205
Figure 14-5. Credibility Factors for Modeling and Simulation 210
Figure 14-6. Sample Credibility Assessment With Threshold Shown in Dark Gray and Achieved Scores in Light Gray 210
Figure 15-1. Additive Manufacturing Process and Related Draft Guidance Sections 216
Figure 17-1. Validation Elements 244
Figure 17-2. Surgical Tool Assembly and Laser Seam Weld 245
Figure 17-3. PQ Components 246
Figure 17-4. Fixed Input Factors 247
Figure 17-5. Variable Input Factor Range 247
Figure 17-6. DoE ANOVA Results 248
Figure 17-7. Marginal Means Graph for Burst Pressure 248
Figure 17-8. Optimized Laser Welding Parameters 249
Figure 17-9. PQ Challenge Laser-Welding Parameters 249
Figure 17-10. Weld Location Measurement 250
Figure 17-11. Z-Test Results, PQ Challenge Test 250
Figure 18-1. Disinfectant Application Technique 256
Figure 18-2. Triple Cleaning Effectiveness Demonstrated by Viable Particulate Surface Sampling 257
Figure 18-3. Cleaning Required for New Build Certification 257
Figure 18-4. Example of Pressure Differentials Through an Aseptic Facility 258

Purchased from RAPS Library (library.raps.org) for the exclusive use of unknown.
© 2026 RAPS Library. Please report unauthorized use to raps@raps.org

Tables

Table 3-1. Gap/Remediation Scope 24
Table 3-2. Scope Change Scenarios 24
Table 3-3. Internal Gaps 25
Table 3-4. External Gaps 26
Table 3-5. ISO 11607-1:2006 vs. ISO 11607-1:2019 Requirements 27
Table 4-1. Required TMV Elements 42
Table 4-2. Basis for 30% GRR Rule; Comparison of Observed to Actual Cp 53
Table 5-1. Strategy and Selection of Experimental Designs 59
Table 5-2. Design Strategies by Nuisance Factors 60
Table 5-3. Randomized Block Design 60
Table 5-4. Plackett-Burman Design 63
Table 5-5. Full Factorial Design 64
Table 5-6. Temperature Change Effect 65
Table 5-7. Expanded Design with Interaction Terms 65
Table 5-8. Interaction Effects Calculation Example 65
Table 5-9. Full Factorial Effects Summary 66
Table 5-10. A Fractional Factorial Design 66
Table 6-1. ISO Sterilization Standards/Guidance Documents 78
Table 6-2. FDA Sterilization Grouping 79
Table 6-3. Dry Heat IQ 81
Table 6-4. Common OQ Activities 83
Table 6-5. Methods to Establish Sterilization Dose 85
Table 6-6. VD_{max} Methods 86
Table 6-7. Known Defined BIs 87
Table 6-8. Dose Audits 91
Table 7-1. DMAIC Model 98
Table 7-2. DMADV Model 99
Table 7-3. SIPOC Map 100
Table 9-1. TIR 30 Acceptance Criteria 130
Table 10-1. Examples of Risk-Based Testing 150
Table 11-1. UDI Impact on Existing Regulations 163
Table 11-2. 62 Attributes for Each Device Identifier 168
Table 13-1. Statistical Error 188
Table 13-2. CTQ Risk Levels 189
Table 13-3. K-Values From ISO-16269-6 195
Table 13-4. Noninferiority Sample Sizes 197
Table 13-5. Confidence and Reliability for C=0 Plans 198
Table 14-1. NASA Modeling and Simulation Risk Matrix 209
Table 18-1. Issues Leading to a Worst-Case Event 254

Purchased from RAPS Library (library.raps.org) for the exclusive use of unknown.
© 2026 RAPS Library. Please report unauthorized use to raps@raps.org

Purchased from RAPS Library (library.raps.org) for the exclusive use of unknown.
© 2026 RAPS Library. Please report unauthorized use to raps@raps.org

Author Acknowledgments

RAPS and editor, Robert Falcone, PhD, FRAPS, FTOPRA, thank the following subject matter experts for sharing their experience and knowledge and volunteering their time to contribute to this third edition of *Medical Device Validation Handbook*.

Editor
Robert Falcone, PhD, FRAPS, FTOPRA
Regulatory Manager
Integrated DNA Technologies IDT

Authors
Wes Bloemker, MBA
Retired

Anthony Carra, MAS, CMQ/OE, PMP
Owner/Principal Consultant
Business Improvement Group

Jay Crowley, MS
Vice President, Medical Devices and UDI Practice Lead
USDM Life Sciences

David W. DiVaccaro, MS
Principal
DiVaccaro Consulting Group, LLC

Courtney Divine
Senior Packaging Engineer
Network Partners Group

Brian K Farison
Technical Fellow
Network Partners Group

Brett D. Hofman
Senior Packaging Engineer
Network Partners Group

Beth Kroeger-Fahnestock
Director, Biopharma Production Chemicals, New Product Introductions
Avantor Sciences

John E. Lincoln
Owner, Principal Consultant
J. E. Lincoln and Associates LLC

Gerry A. O'Dell, MS, AAMI Fellow
Owner/President
Gerry O'Dell Consulting

Rod Patch, MBA
Senior Director, Package Engineering, Product Labeling & Digital Product Information
Johnson & Johnson Vision

James N Polarine Jr., MA
Senior Technical Service Manager
STERIS Corporation

Steven G Richter, PhD, MS, RAC-US
Senior Regulatory Microbiologist
Richco Laboratories LLC

Lisa A. Schaller, MS
Director, Quality Assurance
Varian Medical Systems, a Siemens Healthineers company

David W. Steinmeier, MBA
Owner
microJoining Solutions

Heather A. Valley, MS, RAC-Global
Director Regulatory Affairs
Network Partners Group

Steven L Walfish, MBA, MS
Director, Global Technical Operations Statistics
AstraZeneca

Timothy Wech, MSE, PE
VP, IT and PMO
Network Partners Group

Purchased from RAPS Library (library.raps.org) for the exclusive use of unknown.
© 2026 RAPS Library. Please report unauthorized use to raps@raps.org